259809-70-6

Basic information

• Product Name: 1H-Isoindole-1,3(2H)-dione, 2-[2-[2-[(1E)-2-phenylethenyl]-4-oxazolyl]ethyl]-
• CAS NO: 259809-70-6
• Molecular Formula: C21H16N2O3
• Molecular Weight: 344.37
• Mol File: 259809-70-6.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1H-Isoindole-1,3(2H)-dione, 2-[2-[2-[(1E)-2-phenylethenyl]-4-oxazolyl]ethyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Isoindole-1,3(2H)-dione, 2-[2-[2-[(1E)-2-phenylethenyl]-4-oxazolyl]ethyl]-(259809-70-6)
• EPA Substance Registry System: 1H-Isoindole-1,3(2H)-dione, 2-[2-[2-[(1E)-2-phenylethenyl]-4-oxazolyl]ethyl]-(259809-70-6)

Safety Data

• Hazardous Substances Data: 259809-70-6(Hazardous Substances Data)

Usage

Molecular structure

1H-Isoindole-1,3(2H)-dione core with a substituted 2-phenylethenyl group and a 4-oxazolyl moiety.

Ethyl linker

Connects the two substituents within the compound.

Potential applications

Medicinal chemistry and material sciences.

Presence of functional groups

Associated with bioactive molecules and materials with specific physicochemical properties.

Further research needed

To fully understand the potential uses and properties of this compound.

Upstream product

• 259809-69-3 2-{2-[(E)-2-Phenylethenyl]oxazol-4-yl}-1-ethanol 
• 136918-14-4 phthalimide 
• 1972-28-7 diethylazodicarboxylate 
• 259809-67-1 2-[(E)-2-phenylethenyl]oxazole-4-carbaldehyde 
• 259809-68-2 2-[(E)-2-Phenylethenyl]-4-vinyloxazole 

Downstream Products

• 259809-71-7 4-[2-(tert-butoxycarbonylamino)ethyl]-2-(trans-β-styryl)oxazole 
• 259809-72-8 5-(tert-butoxycarbonyl)-2-(trans-β-styryl)-4,5,6,7-tetrahydrooxazolo[5,4-c]pyridine 
• 259809-74-0 5-(tert-butoxycarbonyl)-2-methoxycarbonyl-4,5,6,7-tetrahydrooxazolo[5,4-c]pyridine 

Relevant articles and documents

Design, synthesis, and biological activity of novel factor Xa inhibitors: Improving metabolic stability by S1 and S4 ligand modification

Serine protease factor xa (fXa) inhibitor 1 showed good ex vivo anti-fXa activity upon oral administration in rats. However, it has been revealed that 1 had low metabolic stability against human liver microsomes. To improve the metabolic stability, we att

DIAMINE DERIVATIVES

A compound represented by formula (1):Q1-Q2-To-N(R1) -Q3-N(R2)-T1-Q4 [wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 represents the following group: (wherein Q5 is an alkylene group having 1 to 8 carbon atoms, or the like); and T0 and T1 are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

DIAMINE DERIVATIVES

A compound represented by the general formula (1):Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.